Core Viewpoint - The innovative drug sector is experiencing a rebound, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a positive performance after a brief decline, indicating renewed investor interest in the sector [1][3]. Company Performance - LIZHU Pharmaceutical reported a mid-year revenue of approximately 6.272 billion yuan, a slight decrease of 0.17% year-on-year, while net profit attributable to shareholders increased by 9.4% to about 1.281 billion yuan [2]. - The company has 39 products in the research pipeline, with 13 in the registration phase, 4 in Phase III clinical trials, 2 in process validation/BE phase, and 4 in Phase II clinical trials [2]. Industry Trends - High-level leaders emphasized the need for increased high-quality technological supply and policy support for the biopharmaceutical industry, aiming to enhance the quality and efficiency of drug development [3]. - CICC expressed optimism about the long-term development trend of innovative drugs, highlighting the advantages of domestic engineers, abundant clinical resources, and supportive policies [3]. - The innovative drug sector is transitioning from a follower to a leader in innovation, with domestic products expected to significantly participate in the global market over the next decade [3]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain [3]. - The index has shown a remarkable year-to-date increase of 101.58%, outperforming the Hang Seng Index and the Hang Seng Tech Index by 78.08 and 79.53 percentage points, respectively [6][7].
午后再度上攻！政策暖风频吹，高人气港股通创新药ETF（520880）涨逾1%，丽珠医药绩后涨超5%